




13TH
INTERNATIONAL WORKSHOP ON MULTIPLE ENDOCRINE NEOPLASIA

IWMEN 2012

Final Program & Abstract Book

Liège 5-8 September, 2012

Wednesday September 5th**Wednesday September 5th, 2012****SPECIAL FOCUS SESSION: AGGRESSIVE PITUITARY ADENOMAS & CARCINOMAS**

Chairs: Philippe Chanson (Paris, France) & Albert Beckers (Liège, Belgium)

Time	Title	Presenter
11.00-11.20	Pathological markers of aggression in pituitary adenomas: focus on MEN1	Jacqueline Trouillas (Lyon, France)
11.20-11.40	Are there imaging markers for pituitary tumor aggressiveness?	Jean-François Bonneville (Besançon, France)
11.40-12.00	AIP status as clinical indicator of aggressiveness in pituitary adenoma patients	Marie-Lise Jaffrain-Rea (L'Aquila, Italy)
12.00-12.20	Break	
12.20-12.40	Aggression & Resistance in Somatotropinoma: Molecular Mechanisms	Marily Theodoropoulou (Münich, Germany)
12.40-13.00	Pituitary carcinoma: Current status of temozolomide	Gérald Raverot (Lyon, France)
13.00-13.35	The Liège Acromegaly Survey: First data in 3000 patients	Patrick Petrossians (Liège, Belgium)
13.35-14.15	Rational use of genetic testing in patients with pituitary adenomas and their families	Albert Beckers (Liège, Belgium)

Wednesday September 5th, 2012

OPENING CEREMONY

Time	Title	Presenter
15.35-15.45	Welcome to the 13th IWMEN, Liège 2012	Albert Beckers (Chairman, Local Organizing Committee, Liège, Belgium)

F.I.R.M.O. FOUNDATION MEDAL PRESENTATION

Time	Title	Presenter
15.45-16.00	Presentation of the Parathyroid Medal to Raj Thakker, University of Oxford	Maria-Luisa Brandi (Florence)

SYMPOSIUM 1: PANCREATIC & GASTROINTESTINAL NEUROENDOCRINE TUMORS

Time	Title	Presenter
16.00-16.25	S1.1: Optimum treatment regimens for advanced pancreatic neuroendocrine tumors.	P. Ruzsiewicz (Hôpital Beaujon, Clichy, France)
16.25-16.50	S1.2: Pancreas-preserving pancreatectomy for neuroendocrine tumors.	H. Dralle (Univ. Halle-Wittenberg, Germany)
16.50-17.15	S1.3: Combination therapy for the management of advanced gastrointestinal neuroendocrine tumors.	B. Wiedenmann (Charité Berlin, Germany)

Thursday September 6th**Thursday September 6th, 2012****SYMPOSIUM 2: MEN-1 & MENIN**

Time	Title	Presenter
9.00-9.25	S2.1: Update on the structure and interactions of menin	X. Hua (Univ. of Pennsylvania, USA)
9.25-9.50	S2.2: Mortality in MEN-1: findings of the French registry	P. Goudet (CHU Dijon, France)
9.50-10.15	S2.3: Optimal management of parathyroid disease in MEN-1	B. Niederle (Univ. of Vienna, Austria)

Break

10.15-10.30

PLENARY LECTURE 2

Time	Title	Presenter
10.30-11.00	Newer pheochromocytoma and paraganglioma susceptibility genes.	M. Robledo (National Cancer Center and CIBERER, Madrid, Spain)

Thursday September 6th, 2012

SYMPOSIUM 3: MULTIPLE KINASE INHIBITORS IN ENDOCRINE NEOPLASIAS

Time	Title	Presenter
11.15-11.40	S3.1: Clinical experience with vandetanib for the treatment of advanced or metastatic hereditary medullary thyroid cancer.	E. Baudin (Institut Gustave Roussy, Villejuif, France)
11.40-12.05	S3.2: Profile of cabozantinib (XL 184), an oral tyrosine kinase inhibitor in medullary thyroid cancer and other endocrine tumors.	R.F. Gagel (Univ. of Texas, MD Anderson Cancer Center, Houston, U.S.A.)
12.05-12.30	S3.3: Integrating multiple kinase inhibitors into the clinical management of hereditary and multiple endocrine neoplasias.	B.G. Robinson (Univ. of Sydney, Australia)

Lunch (Posters are available for viewing at this time)

12.30-14.00

PLENARY LECTURE 3

Time	Title	Presenter
14.00-14.30	Improving the management of gastroenteropancreatic neuroendocrine tumors: optimizing surgical and medical cooperation.	W.W. de Herder (Erasmus Medical Center, Rotterdam, Netherlands)

Thursday September 6th, 2012

SYMPOSIUM 4: ADRENAL NEOPLASIA

Time	Title	Presenter
14.30-14.55	S4.1: Pathophysiology of macronodular adrenal hyperplasia	A. Lacroix (Univ. of Montreal, Canada)
14.55-15.20	S4.2: Genetics of bilateral tumors of the adrenal cortex.	J. Bertherat (Institut Cochin/Univ. of Paris, France)
15.20-15.45	S4.3: KCNJ5: from sporadic to familial hyperaldosteronism	M.C. Zennaro (Univ. of Paris/AP-HP/INSERM, Paris, France)

Break

15.45-16.00

PLENARY LECTURE 4

Time	Title	Presenter
16.00-16.30	MEN4, MEN5?, MEN6?: Cyclin dependent kinase inhibitors in multiple endocrine neoplasias.	S. Marx (NIH, Bethesda, U.S.A.)

Thursday September 6th, 2012

SYMPOSIUM 5: PARAGANGLIOMA & PHEOCHROMOCYTOMA		
Time	Title	Presenter
16.30-16.55	S5.1: Molecular classification of paraganglioma and pheochromocytoma by integrative genomic approaches.	A.P. Gimenez-Roqueplo (Hôpital Européen Georges Pompidou/INSERM/ Univ. of Paris, France)
16.55-17.20	S5.2: The Paraganglioma Valley: Epidemiology of paragangliomas.	G. Opocher (Univ. of Padova, Italy)
17.20-17.45	S5.3: SDH immunohistochemistry in the diagnosis of hereditary or multiple endocrine neoplasias.	Francine van Nederveen (Erasmus Medical Center, Rotterdam, Netherlands)
ORAL SESSION 1 (18.00-19.20)		
Time (10 min. per presentation)	Title	Presenter
	OP1.1: Creation of a locus-specific database for mutations in the AIP gene	Giampaolo Trevellin (Bart's, London, U.K.)
	OP1.2: The clinical and genetic characteristics of patients with gigantism	Liliya Rostomyan (Univ. Liège, Belgium)
	OP1.3: Should we screen MEN1 gene in addition to AIP, in young patient with isolated sporadic pituitary macroadenoma?	Anne Barlier (Hôpital de la Conception, Marseilles, France)
	OP1.4: Performance of immunohistochemistry vs. conventional genetic screening to detect SDHx mutations in patients with pheochromocytoma and paraganglioma from Belgium	Selda Aydin (Cliniques Universitaires Saint-Luc, Brussels, Belgium)
	OP1.5: Co-existence of pituitary adenoma and phaeochromocytoma/ paraganglioma (PHAEO/PGL) does it represent a new syndrome with a heterogeneous genetic pathogenesis?	Judit Denes (Military Hospital, Hungarian Defence Forces, Budapest, Hungary)

Thursday September 6th, 2012

ORAL SESSION 1 (Continued)		
Time (10 min. per presentation)	Title	Presenter
	OP1.6: Identification of chromosome 11 parental origin in a population with endemic PGL1 syndrome	Sara Bobisse (Istituto Oncologico Veneto, Padova, Italy)
	OP1.7: A rare gain-of-function mutation in an inhibitory uORF in the CDKN1B gene causes MEN4 phenotype	Gianluca Occhi (Univ. Padova, Padova, Italy)


Friday September 7th
Friday September 7th, 2012
SYMPOSIUM 6: MEN-2 & RET

Time	Title	Presenter
9.00-9.25	S6.1: Molecular genetics of RET and prognosis in MEN-2.	F. Raue (Heidelberg, Germany)
9.25-9.50	S6.2: Natural history of pheochromocytomas in MEN-2A diagnosed by familial genetic screening.	F. Castinetti (Univ. of Marseilles, France)
9.50-10.15	S6.3: Adrenal function-preserving adrenalectomy in MEN-2.	M. Brauckhoff (Univ of Bergen, Norway)

Break

10.15-10.30

PLENARY LECTURE 5

Time	Title	Presenter
10.30-11.00	What can mice tell us about men(in).	C.X. Zhang (Lyon Cancer Research Center, Lyon, France)

Friday September 7th, 2012

SYMPOSIUM 7: PARATHYROID DISEASE

Time	Title	Presenter
11.15-11.40	S7.1: Diagnostic and therapeutic challenges in parathyroid carcinoma management.	N. Hamdy (Univ. of Leiden, Netherlands)
11.40-12.05	S7.2: Management of chronic post-surgical hypoparathyroidism.	M.L. Brandi (Univ. of Florence, Italy)
12.05-12.30	S7.3: HRPT2 genotype-phenotype correlations in parathyroid disease.	L. Groussin (Institut Cochin/Univ. of Paris 5, France)

Lunch (Posters are available for viewing at this time)

12.30-13.30

PLENARY LECTURE 6

Time	Title	Presenter
13.30-14.00	Genetically-determined disorders of cAMP signaling in endocrine neoplasia syndromes.	C. A. Stratakis (NICHD, Bethesda, U.S.A.)

Friday September 7th, 2012

SYMPOSIUM 8: IMAGING

Chairs:

Time	Title	Presenter
14.00-14.25	S8.1: Nuclear imaging to aid peptide receptor radiotherapy of pancreatic neuroendocrine tumors in MEN-1.	J. Teunissen (Erasmus Medical Center Rotterdam, Netherlands)
14.25-14.50	S8.2: Endoscopic ultrasound of the Pancreas in MEN-1 patients.	D. O'Toole (Trinity College, Dublin, Ireland)

Break

14.50-15.10

ORAL SESSION 2 (15.10-17.40)

Time (10 min. per presentation)	Title	Presenter
	OP2.1: Measurements of CALCA transcripts are useful for the evaluation of asymptomatic RET-mutation carriers and in the follow-up of patients with medullary thyroid cancer and may replace the pentagastrin test	Cleber Camacho (UNIFESP, Sao Paulo, Brazil)

Friday September 7th, 2012

ORAL SESSION 2 Continued (15.10-17.40)

Time (10 min per presentation)	Title	Presenter
	OP2.2: The role of tyrosine kinase inhibitors in a MEN2B patient with metastatic medullary thyroid carcinoma	Monica Tomé (Univ. Liège, Belgium)
	OP2.3: Profile of patients treated for Medullary Thyroid Carcinoma at São Paulo Medical School	Marcos Tavares (Univ. São Paulo School of Medicine, São Paulo, Brazil)
	OP2.4: Pheochromocytoma in Multiple Endocrine Neoplasia Type 2 in Japan: Analysis of a Multicenter Database	Tsuneo Imai (Nagoya University, Nagoya, Japan)
	OP2.5: A study of the Spanish national register of Multiple Endocrine Neoplasia type 2A	Nuria Valdes (Hospital Central de Asturias, Oviedo, Spain)
	Break	
	OP2.6: Could the long-acting somatostatin analogues modify the therapeutic strategy in patients with early stage MEN1-related duodenopancreatic neuroendocrine tumors (NET)s?	Antongiulio Faggiano ("Federico II" University of Naples, Naples, Italy)
	OP2.7: Diagnostic accuracy of chromogranin A, pancreas polypeptide and glucagon in the screening for pancreatic neuroendocrine tumors in Multiple Endocrine Neoplasia type 1 patients	Joanne Marieke de Laat (University Medical Center Utrecht, Utrecht, Netherlands)
	OP2.8: Analysis of penetrance and clinical impact resultant of the diagnosis of multiple endocrine neoplasia type 1-related tumors during childhood and adolescence.	Lourenco Junior Delmar Muniz (School of Medicine, Univ. São Paulo, São Paulo, Brazil)
	OP2.9: Changing manifestations of MEN1 (Burin): increase in occurrence of PNETs	Jane Green (Memorial University, St. John's, Canada)
	OP2.10: Functional characterization of mutations in the Multiple Endocrine Neoplasia type 1 (MEN1) gene suggest therapeutic strategies	Geoffrey Hendy (McGill University, Montreal, Canada)

Friday September 7th, 2012

ORAL SESSION 2 Continued (15.10-17.40)

Time (10 min per presentation)	Title	Presenter
	OP2.11: Association of Type-O Blood with Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1	Allison Weisbrod (NCI, NIH, Bethesda, U.S.A.)
	OP2.12: Comparison between managements of MEN1 and MEN2	Stephen Marx (NIH, Bethesda, U.S.A.)
	OP2.13: Oncoprotein MafB is switched on in early mouse Men1 b-cell neoplastic lesions	Mr Rémy Bonnavion (Cancer Research Center-Lyon Inserm U1052/CNRS 5286, Lyon, France)
	OP2.14: Quinazoline sensitive binding sites are promising new targets for chemotherapy of neuroendocrine tumors	Robert Fuchs (Medical University of Graz, Graz, Austria)

Break

17.40-18.00

HOT TOPICS (18.00-19.40)

Time (25 min per presentation)	Title	Presenter
	HT1: Genome-wide characterization of menin-dependent H3K4me3 in mouse embryonic stem cells undifferentiated or differentiated in vitro into islet-like endocrine cells	Sunita Agarwal (National Institutes of Health, Bethesda, U.S.A.)
	HT2: The Cdk5-p25 holoenzyme causes neuroendocrine cancer in the thyroid	James Bibb (Univ. Texas Southwestern Medical Center, Dallas, Texas, U.S.A.)

Friday September 7th, 2012

HOT TOPICS (Continued)

Time (20 min per presentation)	Title	Presenter
	HT3: Survival and natural course of patients with thymic and bronchopulmonary neuroendocrine tumor in Multiple Endocrine Neoplasia type 1	Joanne Marieke de Laat (University Medical Center Utrecht, Utrecht, Netherlands)
	HT4: Menin is required to maintain bone mass in older mice	Geoffrey Hendy (McGill University, Montreal, Canada)

CONGRESS DINNER 20.00

Palais de Princes Evêques, Liège

Saturday September 8th

Saturday September 8th, 2012

ORAL SESSION 3 (9.10-9.30)

Time (10 min per presentation)	Title	Presenter
	OP3.1: Radiofrequency ablation of pulmonary metastases in parathyroid carcinoma: an alternative therapy for severe refractory hypercalcemia.	Lourenco Junior Delmar Muniz (School of Medicine, Univ. São Paulo, São Paulo, Brazil)
	OP3.2: Clinical features of primary hyperparathyroidism (PHPT) in patients with parathyroid carcinoma.	Natalia Mokrysheva (Endocrinology Research Centre, Moscow, Russia)

Saturday September 8th, 2012

SPECIAL FOCUS SESSION: PARATHYROID CARCINOMA RESEARCH

Chairs: Raj Thakker (Oxford, U.K.) and Albert Beckers (Liège, Belgium)

Time	Title	Presenter
9.30-9.50	Diagnosis of parathyroid carcinoma: potential role of PTH laboratory assays	Etienne Cavalier (Univ. of Liège, Liège, Belgium)
9.50-10.10	Molecular genetics of parathyroid carcinoma	Raj Thakker (Univ. Oxford, U.K.)
10.10-10.25	Break	
10.25-10.45	Diagnosis of parathyroid carcinoma: pathological and molecular genetic challenges	Hans Morreau/Naveen Hamdy (Univ Leiden, Netherlands)
10.45-11.05	Therapy of parathyroid carcinoma: update on anti-PTH immunotherapy	Daniela Betea (Univ. of Liège, Liège, Belgium)
11.05-11.30	Discussion on tools for improved research and collaboration: patient databases, tumor biobanks, common goals and purposes	Roundtable discussion

CLOSING CEREMONY

Time	Title	Presenter
11.40-11.45	Closure of the 13th IWMEN, Liège 2012	Albert Beckers (Chairman, Local Organizing Committee, Liège, Belgium)